Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line
Authors
Keywords
miR-145, colo205, Drug resistance, Vemurafenib
Journal
TUMOR BIOLOGY
Volume 35, Issue 4, Pages 2983-2988
Publisher
Springer Nature
Online
2013-11-19
DOI
10.1007/s13277-013-1383-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
- (2013) M Avgeris et al. BRITISH JOURNAL OF CANCER
- MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors
- (2013) Marlene Adammek et al. FERTILITY AND STERILITY
- Downregulation of miR-145 Expression in Oral Squamous Cell Carcinomas and Its Clinical Significance
- (2013) Ling Gao et al. ONKOLOGIE
- Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells
- (2012) Ming Shi et al. JOURNAL OF PATHOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression
- (2012) A Pagliuca et al. ONCOGENE
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
- (2011) H. Yang et al. CANCER RESEARCH
- MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer
- (2011) Seong O. Suh et al. CARCINOGENESIS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1
- (2011) William CS Cho et al. RNA Biology
- miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
- (2010) T Chiyomaru et al. BRITISH JOURNAL OF CANCER
- Colorectal cancer
- (2010) David Cunningham et al. LANCET
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-145-dependent targeting of Junctional Adhesion Molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness
- (2010) M Götte et al. ONCOGENE
- MicroRNA-145 Targets YES and STAT1 in Colon Cancer Cells
- (2010) Lea H. Gregersen et al. PLoS One
- miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells
- (2009) R Spizzo et al. CELL DEATH AND DIFFERENTIATION
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- p53 represses c-Myc through induction of the tumor suppressor miR-145
- (2009) M. Sachdeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now